Business
Covalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan
Covalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"\n\n\n\nCovalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCovalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan\nCanada NewsWire\nMISSISSAUGA, ON, Feb. 9, 2016\n\n\n\nMISSISSAUGA, ON, Feb. 9, 2016 /CNW/ - Covalon Technologies Ltd. (the \"Company\" or \"Covalon\") (TSXV: COV), an advanced medical technologies company, has announced a licensing agreement with the University of Michigan's Center for Integrative Research in Critical Care (\"MCIRCC\"), whereby Covalon has licensed intellectual property from MCIRCC that, when commercialized, could prevent or reduce the occurrence of Ventilator-Associated Pneumonia (\"VAP\"), a potentially devastating hospital acquired infection, and the most common nosocomial infection in critically ill patients.1 \n\nCovalon has commenced the development of a product prototype, based on work performed by Dr. Kevin Ward at MCIRCC and colleagues at Virginia Commonwealth University. This work formed the basis for the patents and intellectual property licensed by Covalon. The commercialized product is expected to be inserted into a ventilated patient's mouth, regardless of the brand of endotracheal tube or ventilator used, to provide antimicrobial protection against the pathogens commonly associated with VAP.  \n\nHospital acquired pneumonia can occur in both mechanically ventilated and non-ventilated patients, and can greatly extend their hospital stay, resulting in mortality rates of up to 50% of critically ill patients who acquire VAP while in intensive care.2 VAP occurs in as much as 65% of mechanically ventilated ICU patients and has an average cost of $40,000 per episode to U.S. hospitals to treat.3\n\n\"VAP affects the most vulnerable of patients and many symptoms typically associated with pneumonia are masked or absent because patients are often sedated and unable to communicate,\" stated Dr. Ward.  \"Patients requiring mechanical ventilati...